Leveraging Biomarkers and Translational Medicine for Preclinical Safety – Lessons for Advancing the Validation of Alternatives to Animal Testing
Like
Be the first to like this
Thomas Hartung1,2, Nicholas M. P. King3, Nicole Kleinstreuer4, Marcel Leist2,5 and Danilo A. Tagle6 1Center for Alternatives to Animal Testing (CAAT), Doerenkamp-Zbinden-Chair for Evidence-based Toxicology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; 2CAAT-Europe, University of Konstanz, Germany; 3Critical Path Institute, Tucson, AZ, USA; 4National Institute of Health, National Institute for Environmental Health Sciences, DTT/NICEATM, Durham, NC, USA; 5In vitro Toxicology and Biomedicine, University of Konstanz, Konstanz, Germany; 6National Institute of Health, National Center for Advancing Translational Sciences (NCATS), Bethesda, MD, USA
Recommended Content
Highlighted and sponsored news., Free Open Access Chip papers., Free Open Access Organoid papers., WORCs 4 me! Introduce yourself, find an expert/start a chat/post a paper/ask a question?, Imperial College London, LION, Queen Mary Centre for Predictive in vitro Models , Cancer in 3D - Free watch video room. Registered WORC Members only.
October Newsletter launches WORD+2026 with 50% off a LIMITED Number of researcher tickets.
Please sign in or register for FREE
If you are a registered user on WORC.Community, please sign in